|
|
Study Finds Bias in Drug Studies
October 7, 2006
Tests and reviews of drugs that are supported by the
pharmaceutical industry should perhaps be read with more than a hint of
skepticism. So advices a new study in the British Medical Journal, which
finds these industry supported reviews are more likely to reach favorable
conclusion on drugs, than independent reviews.
According to the authors, bias in drug trials is common and often favors the
trial sponsor's product. To balance this effect, independent reviews --
which can have a more critical and systematic approach -- are essential to
ensure doctors and other health professionals have the information they
need.
The authors, based in Denmark, compared the results of 24 pairs of reviews
conducted by different people on the same drugs.
Compared to reviews supported by the pharmaceutical industry, reviews
undertaken by the Cochrane Collaboration -- an independent body -- were of a
higher quality and were more likely to address the potential for bias in the
review.
Of seven industry-supported reviews, all recommended the experimental drug
without reservation, while none of the corresponding Cochrane reviews
reached the same conclusion.
Six of the eight Cochrane reviews analyzed had reservations about the
quality or relevance of the trials or their findings and two of them noted
that the effect decreased with increasing number of patients in the trial.
Seven mentioned higher cost of the experimental drug as a problem.
In contrast, none of the industry-supported reviews mentioned higher cost as
a problem, and two claimed that the experimental drug was cost-effective.
The researchers also found that the reviews with not-for-profit support or
no support had cautious conclusions similar to the Cochrane reviews.
The authors conclude that industry-supported reviews should be read with
caution. They also want greater transparency, including the inclusion of
more information on methodology and the estimated effects of the drugs, in
order to allow readers to judge the reliability of drug reviews.
SOURCE:ConsumerAffairs.Com
|
|
|